Treats plaque psoriasis. ANDA 208124, held by Lupin. Desoximetasone.
As of Nov 15, 2026, ANDA 208124 (Desoximetasone), held by Lupin, was first approved by FDA on Mar 16, 2018, with 0 approved supplements and 0 published complete response letters.
Desoximetasone topical spray, 0.25% is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 16, 2018 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Desoximetasone0.25% · spray;topical | Desoximetasone | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
